More than 28 million people worldwide are living with heart valve disease, and the numbers are climbing. In the U.S., the condition contributes to ...

Detailed price information for Edwards Lifesciences Corp (EW-N) from The Globe and Mail including charting and trades.

People living with aortic stenosis (AS) could gain earlier access to innovative care and treatment thanks to a new effort ...

Late-breaking results from clinical trials, debates about lifestyle choices and cardiovascular risk, and improving clinical care with generative AI are among the topics being presented by UC San ...

People living with aortic stenosis (AS) could gain earlier access to innovative care and treatment thanks to a new effort ...

The Phase 2, randomized, double-blind clinical trial included 23 patients randomized to either 200 mg ataciguat (n=12) or placebo (n=11) once daily for a 12-month period. The primary Phase 2 clinical ...

People living with aortic stenosis (AS) could gain earlier access to innovative care and treatment thanks to a new effort ...

JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, today announced highlights from the 2025 Transcatheter Cardiovascular Therapeutics (TCT) ...

Risk stratification of patients with chest pain has traditionally focused on identifying obstructive coronary artery disease (CAD). Using this traditional approach, many symptomatic individuals are ...

Results from the PREVUE-VALVE study suggest that there are currently at least 4.7 million people aged 65–85 living with moderate or greater valvular heart disease (VHD) in the United States, and at ...

Cardiovascular disease (CVD), a composite of coronary heart disease (CHD), cerebrovascular disease, and heart failure, ...

To understand the benefits of cardiac rehabilitation, you can trust decades of research—or listen to Taelur Littlejohn's ...